Cognitive impairment associated with depression in the elderly

Journal of Clinical Psychiatry

Volumn 68, Issue 10, 2007, Pages 1601-1612

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID PRECURSOR PROTEIN; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ASCORBIC ACID; BENZODIAZEPINE; BETA SECRETASE INHIBITOR; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONEPEZIL; ENZYME INHIBITOR; FLUOXETINE; FLURBIPROFEN; FOLIC ACID; GALANTAMINE; GLYCOGEN SYNTHASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPNOTIC SEDATIVE AGENT; LITHIUM; MEMANTINE; MUSCARINIC AGENT; NARCOTIC AGENT; NIMODIPINE; PROTEIN KINASE C ACTIVATOR; RIVASTIGMINE; TAU PROTEIN; VITAMIN B COMPLEX;

AEROBIC EXERCISE; ALZHEIMER DISEASE; AMNESIA; BRAIN ATROPHY; BRAIN BLOOD VESSEL; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; EMOTION; ENZYME ACTIVATION; EXERCISE; FUNCTIONAL DISEASE; GENETIC RISK; GERIATRIC PATIENT; HIPPOCAMPUS; HUMAN; HYPERTENSION; IMMUNIZATION; INTELLIGENCE; LIFE STRESS; MENINGOENCEPHALITIS; NERVE DEGENERATION; NEUROANATOMY; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; OLFACTORY BULB; OLFACTORY TRACT; OUTCOME ASSESSMENT; PASSIVE IMMUNIZATION; PATHOLOGICAL ANATOMY; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SOCIAL BEHAVIOR; VASCULAR DISEASE;

EID: 35948987577     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n1020     Document Type: Review

References (96)

1. He W, Sengupta M, Velkoff VA, et al. 65+ in the United States: 2005, US Census Bureau, Current Population Report, P23-209. Washington, DC: US Government Printing Office; 2005
2. Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007;39:168-177
3. McGowan E, Eriksen J, Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet 2006;22:281-289
4. Gandy S. The role of cerebral amyloid β accumulation in common forms of Alzheimer disease. J Clin Invest 2005;115:1121-1129
5. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A 2006;103:5644-5651
6. Formichi P, Battisti C, Radi E, et al. Cerebrospinal fluid tau, Aβ, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. J Cell Physiol 2006;208:39-46
7. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337-1342
8. Vardy ER, CaKo AJ, Hooper NM. Proteolytic mechanisms in Aβ metabolism: therapeutic implications for Alzheimer's disease. Trends Mol Med 2005;11:464-472
9. Singer O, Marr RA, Rockenstein E, et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 2005;8:1343-1349
10. Dominguez D, Tournoy J, Hartmann D, et al. Phenotypic and biochemical analysis of BACE1- and BACE2-deficient mice. J Biol Chem 2005;280:30797-30806
11. Hussain I, Hawkins J, Harrison D, et al. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. J Neurochem 2007;100:802-809
12. Wolfe MS. The γ-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry (Mose) 2006;45:7931-7939
13. Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. J Clin Invest 2003;112:440-449
14. Geerts H. Drug evaluation: (R)-flurbiprofen - an enantiomer of flurbiprofen for the treatment of Alzheimer's disease. IDrugs 2007;10:121-133
15. Fisher A, Pittel Z, Haring R, et al. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy. J Mol Neurosci 2003;20:349-356
16. Hooper NM, Turner AJ. The search for alpha secretase and its potential as a therapeutic approach to Alzheimer's disease. Curr Med Chem 2002;9:1107-1119
17. Eckman EA, Adams SK, Troendle FJ, et al. Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem 2006;281:30471-38478
18. Björk BF, Katzov H, Kehoe P, et al. Positive association between risk for late-onset Alzheimer disease and genetic variation in IDE. Neurobiol Aging 2007;28:1374-1380
19. Cacquevel M, Launay S, Castel H, et al. Ageing and amyloid-beta peptide deposition contribute to an impaired brain tissue plasminogen activator activity by different mechanisms. Neurobiol Dis 2007;27:164-173
20. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse [letter]. Nature 1999;400:173-177
21. Brendza RP, Holtzman DM. Aβ immunotherapies in mice and men. Alzheimer Dis Assoc Disord 2006;20:118-123
22. Holtzman DM, Bales KR, Paul SM, et al. Aβ immunization and anti-Aβ antibodies: potential therapies for the prevention and treatment of Alzheimer's disease. Adv Drug Deliv Rev 2002;54:1603-1613
23. Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 2006;6:404-416
24. Noble W, Planel E, Zehr C, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 2005;102:6990-6995
25. Phiel CJ, Wilson CA, Lee VM, et al. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides [letter]. Nature 2003;423:435-439
26. Bertram L, McQueen MB, Mullin K, et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007;39:17-23
27. Barnes DE, Alexopoulos GS, Lopez OL, et al. Depressive symptoms, vascular diease, and mild cognitive impairment: findings from the Cardiovascular Health Study. Arch Gen Psychiatry 2006;63:273-279
28. Devanand DP, Sano M, Tang MX, et al. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry 1996;53:175-182
29. Bassuk SS, Berkman LF, Wypij D. Depressive symptomatology and incident cognitive decline in an elderly community sample. Arch Gen Psychiatry 1998;55:1073-1081
30. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J Am Geriatr Soc 1996;44:1078-1081
31. Devanand DP, Jacobs DM, Tang MX, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry 1997;54:257-263
32. Schelben HR, ed. Phelps ME, Mazziotta J. Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and Heart. New York, NY: Raven Press; 1986
33. Tekin S, Cummings JL. Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. J Psychosom Res 2002;53:647-654
34. Thompson PM, Hayashi KM, de Zubicaray G, et al. Dynamics of gray matter loss in Alzheimer's disease. J Neurosci 2003;23:994-1005
35. Sheline YI, Wang PO, Gado MH, et al. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A 1996;93:3908-3913
36. Sheline YI, Sanghavi M, Mintun MA, et al. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent depression. J Neurosci 1999;19:5034-5043
37. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry 2003;160:1516-1518
38. Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006;355:2652-2663
39. Rapp MA, Schnaider-Beeri M, Grossman HT, et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry 2006;63:161-167
40. Friedland RP, Fritsch T, Smyth KA, et al. Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members. Proc Natl Acad Sci U S A 2001;98:3440-3445
41. Colcombe SJ, Erickson KI, Raz N, et al. Aerobic fitness reduces brain tissue loss in aging humans. J Gerontol A Biol Sci Med Sci 2003;58:176-180
42. Sapolsky RM. Glucocorticoids, stress, and their adverse neurological effects: relevance to aging. Exp Gerontol 1999;34:721-732
43. Newcomer JW, Selke G, Melson AK, et al. Decreased memory performance in healthy humans induced by stress-level corticol treatment. Arch Gen Psychiatry 1999;56:527-533
44. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301:386-389
45. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-809
46. Krishnan KR, Taylor WD, McQuoid DR, et al. Clinical characteristics of magnetic resonance imaging-defined subcortical ischemic depression. Biol Psychiatry 2004;55:390-397
47. MacFall JR, Payne ME, Provenzale JE, et al. Medial orbital frontal lesions in late-onset depression. Biol Psychiatry 2001;49:803-806
48. Steffens DC, Krishnan KR, Crump C, et al. Cerebrovascular disease and evolution of depressive symptoms in the cardiovascular health study. Stroke 2002;33:1636-1644
49. Steffens DC, Helms MJ, Krishnan KR, et al. Cerebrovascular disease and depression symptoms in the cardiovascular health study. Stroke 1999;30:2159-2166
50. Taylor WD, MacFall JR, Provenzale JM, et al. Serial MR imaging of volumes of hyperintense white matter lesions in elderly patients: correlation with vascular risk factors. Am J Roentgenol 2003;181:571-576
51. Taylor WD, Steffens DC, MacFall JR, et al. White matter hyperintensity progression and late-life depression outcomes. Arch Gen Psychiatry 2003;60:1090-1096
52. Taragano FE, Allegri R, Vicario A, et al. A double blind, randomized clinical trial assessing the efficacy and safety of augmenting standard antidepressant therapy with nimodipine in the treatment of 'vascular depression.' Int J Geriatr Psychiatry 2001;16:254-260
53. Taragano FE, Bagnatti P, Allegri RF. A double-blind, randomized clinical trial to assess the augmentation with nimodipine of antidepressant therapy in the treatment of "vascular depression." Int Psychogeriatr 2005;17:487-498
54. Mlekusch W, Mlekusch I, Minar E, et al. Is there improvement of "vascular depression" after carotid artery stent placement? Radiology 2006;240:508-514
55. Steffens DC, MacFall JR, Payne ME, et al. Grey-matter lesions and dementia [letter]. Lancet 2000;19:1686-1687
56. Selnes OA, Vinters HV. Vascular cognitive impairment. Nat Clin Pract Neurol 2006;2:538-547
57. McGuinness B, Todd S, Passmore P, et al. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev 2006:CD004034
58. Rands G, Orrel M, Spector A. Aspirin for vascular dementia. Cochrane Database Syst Rev 2000:CD001296
59. Devine ME, Rands G. Does aspirin affect outcome in vascular dementia? a retrospective case-notes analysis. Int J Geriatr Psychiatry 2003;18:425-431
60. Malouf M, Grimley EJ, Areosa SA. Folic acid with or without vitamin B12 for cognition and dementia. Cochrane Database Syst Rev 2003:CD004514
61. Lopez-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev 2002:CD000147
62. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006:CD001190
63. Craig D, Birks J. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev 2006:CD004746
64. McShane R, Sastre AA, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006:CD003154
65. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-1992
66. Tabert MH, Manly JJ, Liu X, et al. Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. Arch Gen Psychiatry 2006;63:916-924
67. Tabert MH, Albert SM, Borukhova-Milov L, et al. Functional deficits in patients with mild cognitive impairment: prediction of AD. Neurology 2002;58:758-764
68. Devanand DP, Pelton GH, Zamora D, et al. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Arch Neurol 2005;62:975-980
69. Tierney MC, Szalai JP, Snow WG, et al. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology 1996;46:149-154
70. Devanand DP, Pradhaban G, Liu X, et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 2007;68:828-836
71. Devanand DP, Michaels-Marston KS, Liu X, et al. Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. Am J Psychiatry 2000;157:1399-1405
72. Gsell W, De Sadeleer C, Marchalant Y, et al. The use of cerebral blood flow as an index of neuronal activity in functional neuroimaging: experimental and pathophysiological considerations. J Chem Neuroanat 2000;20:215-224
73. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001;286:2120-2127
74. Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-234
75. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-319
76. Devanand DP. The course of treatment of patients with questionable dementia. In: Syllabus and Proceedings Summary of the 160th Annual Meeting of the American Psychiatric Association; May 20, 2007; San Diego, Calif. Industry Supported Symposia No. 12E:20
77. Visser PJ, Verhey FR, Scheltens P, et al. Diagnostic accuracy of the Preclinical AD scale (PAS) in cognitively mildly impaired subjects. J Neurol 2002;249:312-319
78. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-2388
79. Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002;288:1475-1483
80. Arve S, Tilvis RS, Lehtonen A, et al. Co-existence of lowered mood and cognitive impairment of elderly people in five birth cohorts. Aging (Milano) 1999;11:90-95
81. Geda YE, Knopman DS, Mrazek DA, et al. Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study. Arch Neurol 2006;63:435-440
82. Modrego PJ, Ferrández J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type. Arch Neurol 2004;61:1290-1293
83. Kalayam B, Alexopoulos GS. Prefrontal dysfunction and treatment response in geriatric depression. Arch Gen Psychiatry 1999;56:713-718
84. Alexopoulos GS, Kiosses DN, Murphy C, et al. Executive dysfunction, heart disease burden, and remission of geriatric depression. Neuropsychopharmacology 2004;29:2278-2284
85. Alexopoulos GS, Meyers BS, Young RC, et al. Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry 2000;57:285-290
86. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-2388
87. Petersen RC. Mild cognitive impairment: current research and clinical implications. Semin Neurol 2007;27:22-31
88. Butters MA, Becker JT, Nebes RD, et al. Changes in cognitive functioning following treatment of late-life depression. Am J Psychiatry 2000;157:1949-1954
89. Devanand DP, Pelton GH, Marston K, et al. Sertraline treatment of elderly patients with depression and cognitive impairment. Int J Geriatr Psychiatry 2003;18:123-130
90. Nebes RD, Pollock BG, Houck PR, et al. Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine. J Psychiatr Res 2003;37:99-108
91. Lechevallier-Michel N, Molimard M, Dartigues JF, et al. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study. Br J Clin Pharmacol 2005;59:143-151
92. Larson EB, Wang L, Bowen JD, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med 2006;144:73-81
93. Dunn AL, Trivedi MH, Kampert JB, et al. Exercise treatment for depression: efficacy and dose response. Am J Prev Med 2005;28:1-8
94. Ott A, Breteler MM, Harskamp F, et al. Prevalence of Alzheimer's disease and vascular dementia: association with education: The Rotterdam study. BMJ 1995;310:970-973
95. Verghese J, Lipton RB, Katz MJ, et al. Leisure activities and the risk of dementia in the elderly. N Engl J Med 2003;348:2508-2516
96. Glass TA, De Leon CF, Bassuk SS, et al. Social engagement and depressive symptoms in late life: longitudinal findings. J Aging Health 2006;18:604-628